<?xml version="1.0" encoding="UTF-8"?>
<p id="para40">Third, surfactant, inhaled nitric oxide, various ventilation methods, and extracorporeal life support cannot be suggested for every patient, because no evidence-based data exist. Epidemiologically, the priority is to diagnose neonatal acute respiratory distress syndrome (ARDS) according to the age-specific definition (the so-called Montreux definition of neonatal ARDS
 <xref rid="bib3" ref-type="bibr">
  <sup>3</sup>
 </xref>) and use it to classify clinical severity. This allows production of solid epidemiology data and comparisons between paediatric and adult ARDS statistics. Therapeutics should be used on a case-by-case basis. Respiratory support policy should be guided by a physiology-driven approach and follow the best evidence available in paediatric critical care, according to international guidelines.
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref>
</p>
